This study evaluated the in vitro activity of aztreonam-avibactam and ceftazidime-avibactam against Enterobacterales and *Pseudomonas aeruginosa* isolated from patients with infections in hematology, oncology, and transplant units across U.S. medical centers from 2019 to 2024.
Specific susceptibility rates and MIC data are referenced in the paper but not fully detailed in the provided abstract; aztreonam-avibactam and ceftazidime-avibactam were assessed for activity against these clinically challenging, often drug-resistant pathogens in immunocompromised patient populations.
The study is based on in vitro susceptibility data only, which may not directly predict clinical outcomes; the patient population is limited to hematology, oncology, and transplant units at U.S. centers, limiting generalizability; temporal trends over 2019–2024 may reflect evolving resistance patterns not fully disentangled.
In immunocompromised patients (hematology, oncology, transplant), aztreonam-avibactam and ceftazidime-avibactam offer important options against resistant Enterobacterales and *P. aeruginosa*—clinicians should monitor local susceptibility data in these high-risk units to guide empiric and targeted therapy.
Explore related topics
